Loading…
Reported covered position: Internship for Rep. Mike Rogers (R-MI).
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EISAI INC. via EISAI INC.
2026 · third_quarter · Q3
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Issues related to pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
Source: Senate LDA
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Client: EISAI INC. · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Client: EISAI INC. · Firm: EISAI INC.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program; H.R.9599 Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act)
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Issues related to pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
Pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: EISAI INC. · Firm: EISAI INC.
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI INC. · Firm: EISAI INC.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: EISAI INC. · Firm: EISAI INC.
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Congressionally Directed Medical Research Program (malaria); Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; PBM reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.
General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Proposed Rebate Rule.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.
Tax Relief for American Families and Workers Act of 2024
Client: EISAI INC. · Firm: EISAI INC.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Tax Relief for American Families and Workers Act of 2024
Client: EISAI INC. · Firm: EISAI INC.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: EISAI INC. · Firm: EISAI INC.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.
General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers Drugs; H.R. 5376, Inflation Reduction Act of 2022 (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Proposed Rebate Rule.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.
Issues related to pharmaceutical manufacturing.
Issues related to supply chain manufacturing and tariffs, including: the Section 232 and Section 301 tariff investigations related to branded pharmaceuticals.
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program; H.R.9599 Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI INC. via EISAI INC.
2026 · second_quarter · Q2
Supply chain manufacturing and tariffs, including: the Section 232 and Section 301 tariff investigations related to branded pharmaceuticals.
Pharmaceutical manufacturing.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program.
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI INC. via EISAI INC.
2026 · first_quarter · Q1
Issues related to supply chain manufacturing and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Issues related to pharmaceutical Intellectual Property (IP).
Issues related to pharmaceutical manufacturing.
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI INC. via EISAI INC.
2025 · fourth_quarter · Q4
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; PBM reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Issues related to supply chain and tariffs. Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI INC. via EISAI INC.
2025 · third_quarter · Q3
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.
Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Issues related to supply chain and tariffs. Section 232 tariff investigation on branded pharmaceuticals.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI INC. via EISAI INC.
2025 · second_quarter · Q2
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Congressionally Directed Medical Research Program (malaria); Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.
EISAI INC. via EISAI INC.
2025 · first_quarter · Q1
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.
EISAI INC. via EISAI INC.
2024 · fourth_quarter · Q4
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act ; TRICARE coverage.
Issues related to tax reform.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act; issues related to Medical supply chain. Issues related to intellectual property.
EISAI INC. via EISAI INC.
2024 · third_quarter · Q3
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination NCD for Alzheimer's Drugs; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Medicaid Proposed Rebate Rule; S. 2379 / H.R. 4752, the CHANGE Act. Issues related to intellectual property.
Issues related to tax reform.
EISAI INC. via EISAI INC.
2024 · second_quarter · Q2
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47;improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
EISAI INC. via EISAI INC.
2024 · first_quarter · Q1
General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers therapies; H.R. 5376, Inflation Reduction Act (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Proposed Rebate Rule.
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring Pharmacy Benefit Managers (PBM) Accountability Act; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; ; improvements to the 340B drug discount program.
Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Issues related to supply chain and tariffs.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform. Issues related to Research and Development tax credit.
Issues related to supply chain and tariffs.
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Regulatory and legislative health care issues, including: Alzheimer's drug development; Drug Pricing; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; improvements to the 340B drug discount program; Seniors Access to Critical Medications Act of 2023.; S. 4276 / H.R. 7688, the Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to Medicare and Medicaid, Part D Medicare Program, Part B Medicare Program; Drug Pricing; Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Alzheimers Drugs; H.R. 5376, Inflation Reduction Act of 2022 (PL 117-169) implementation; Center for Medicare and Medicaid Innovation (CMMI) Proposed Accelerated Approval Payment Policy; Center for Medicare and Medicaid Innovation (CMMI) Proposed Rebate Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE